Swog Cancer Research Network

This phase III trial is testing three different drug combinations for people newly diagnosed with multiple myeloma who are considered frail or intermediate-fit and are not getting a stem cell transplant. The study compares three-drug induction regimens followed by either double o…

This phase 3 trial tests whether adding a live biotherapy called MO-03 to standard immunotherapy can help control advanced or metastatic clear cell renal cell carcinoma. MO-03 is designed to improve gut health, which may make immunotherapy work better. About 718 participants will…

This study tests whether combining three targeted drugs (capmatinib, osimertinib, and ramucirumab) works better than two drugs alone for people with advanced non-small cell lung cancer that has specific EGFR and MET gene changes. The drugs block signals that help cancer grow and …

This study tests whether adding a targeted drug called panitumumab to standard chemotherapy helps people with a specific type of advanced pancreatic cancer (KRAS wild-type) live longer. About 94 adults whose cancer has spread or can't be removed will be randomly assigned to get c…

This study is for people with stage IV or returning non-small cell lung cancer who have already had chemotherapy and immunotherapy. It compares the usual two-drug treatment (docetaxel and ramucirumab) to the same two drugs plus a third drug called cemiplimab. The goal is to see i…

This phase 3 trial tests whether adding a stem cell transplant to standard chemotherapy helps people with newly diagnosed AL amyloidosis. About 338 participants will receive either chemo alone or chemo followed by a stem cell transplant. The goal is to see which approach better d…

This study tests a drug called amivantamab, given as a shot under the skin, for people with advanced non-small cell lung cancer that has extra copies of the MET gene. The goal is to see if the drug can shrink tumors or stop them from growing. About 88 participants will take part …

This study tests whether adding ramucirumab to tepotinib works better than tepotinib alone for people with advanced non-small cell lung cancer that has a specific MET gene mutation. About 56 participants will be randomly assigned to one of two treatment groups. The goal is to see…

This study tests whether using biomarker tests to personalize maintenance therapy can help control extensive-stage small cell lung cancer. About 900 participants will receive durvalumab alone or combined with other drugs based on their cancer subtype. The goal is to see if this t…

This study tests whether adding two targeted drugs (mosunetuzumab and/or polatuzumab vedotin) after standard CAR T-cell therapy can help control lymphoma that has returned or not responded to treatment. About 396 adults with certain types of aggressive B-cell lymphoma will be ran…

This study is for men with high-risk prostate cancer who have inherited BRCA1 or BRCA2 gene mutations. It tests whether giving the chemotherapy drug carboplatin before surgery can shrink tumors more effectively. About 44 participants will receive carboplatin, and researchers will…

This phase III trial tests whether adding carboplatin to the standard chemo drug cabazitaxel helps men with metastatic castrate-resistant prostate cancer live longer without their cancer worsening. About 528 men will be randomly assigned to get cabazitaxel alone or cabazitaxel pl…

This study looks at whether giving two chemotherapy drugs (capecitabine and temozolomide) after surgery can prevent or delay the return of high-risk pancreatic neuroendocrine tumors. About 141 people who have had their tumor removed will be randomly assigned to receive the drugs …

This phase II trial compares two chemotherapy combinations—ramucirumab plus paclitaxel versus FOLFIRI—in 94 patients with advanced or treatment-resistant small bowel adenocarcinoma. The goal is to see which regimen better slows cancer growth and extends survival. Participants mus…

This study is for people with early-stage triple-negative breast cancer. It compares a shorter chemo-immunotherapy regimen without anthracyclines (a type of strong chemo) to the usual longer treatment. The goal is to see if the shorter approach works just as well while reducing s…

This study tests whether adding either tazemetostat or zanubrutinib to a standard two-drug therapy (tafasitamab and lenalidomide) can shrink tumors or delay cancer return in people with large B-cell lymphoma that came back or didn't respond to prior treatment. About 227 adults wh…

This phase 3 trial is testing whether adding surgery to remove the prostate or radiation therapy to standard drug treatment helps people with prostate cancer that has spread to other parts of the body. About 1,273 participants will receive either standard therapy alone or standar…

This phase 2 trial compares two treatment combinations for people with BRAF-V600 mutant melanoma that has spread to the brain. One group gets a targeted therapy (encorafenib and binimetinib) plus an immunotherapy (nivolumab), while the other gets two immunotherapies (ipilimumab a…

This phase III trial is testing whether adding surgery to remove the kidney (nephrectomy) to standard immunotherapy drugs helps people with kidney cancer that has spread live longer. About 364 participants will either receive immunotherapy alone or immunotherapy plus surgery. The…

This study tests whether cooling and compressing the arms and legs during taxane chemotherapy can prevent peripheral neuropathy—a common side effect causing numbness, tingling, or pain. About 777 cancer patients will be randomly assigned to one of three approaches: cryocompressio…

This study tests if giving the drug lanreotide before pancreatic surgery can prevent a common complication called a pancreatic fistula, which is a leak of digestive fluids. About 274 people with pancreatic cancer or precancerous lesions will be randomly assigned to receive either…

This large study screens up to 10,000 people with previously treated non-small cell lung cancer to find specific genetic markers in their tumors. Based on those markers, participants may be assigned to a sub-study testing a new targeted therapy or immunotherapy. The goal is to le…

This study looks at how things like age, gender, and other health conditions affect the side effects of immunotherapy in people with solid tumors. Immunotherapy helps the body's immune system fight cancer, but it can cause side effects. The goal is to learn more so doctors can ch…

This study is testing whether using simple blood tests to decide when to do scans is as effective as the usual approach of regular scans for people with advanced breast cancer. About 739 participants will be randomly assigned to either blood test monitoring or standard care. The …

This study tests a website called Current Together after Cancer (CTAC) to see if it helps people who had stage 2 or 3 colorectal cancer surgery get the recommended follow-up tests. Many survivors miss these important check-ups, which can catch cancer if it comes back early. The w…

This study looks at heart problems in people with HER2+ breast cancer that has spread. All participants are taking trastuzumab-based treatment. The main goal is to see how often heart issues occur, especially in those also taking beta blockers or similar heart medications. A smal…